Related references
Note: Only part of the references are listed.Vertebral Fractures: Clinical Importance and Management
D. L. Kendler et al.
AMERICAN JOURNAL OF MEDICINE (2016)
Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study
Sumit R. Majumdar et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Type 2 diabetes and the skeleton: new insights into sweet bones
Vikram V. Shanbhogue et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
Ofri Mosenzon et al.
DIABETES CARE (2015)
The Impact of Diabetes and Diabetes Medications on Bone Health
Matthew P. Gilbert et al.
ENDOCRINE REVIEWS (2015)
Trabecular Bone Score as an Indicator for Skeletal Deterioration in Diabetes
Jung Hee Kim et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review
A. Palermo et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs
Johanna H. M. Driessen et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2015)
Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials
Bin Su et al.
ENDOCRINE (2015)
Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
Johanna H. M. Driessen et al.
BONE (2014)
Increased Risk of Fracture and Postfracture Adverse Events in Patients With Diabetes: Two Nationwide Population-Based Retrospective Cohort Studies
Chien-Chang Liao et al.
DIABETES CARE (2014)
Use of glucagon-like peptide-1 receptor agonists and bone fractures: A meta-analysis of randomized clinical trials
Guillaume Mabilleau et al.
JOURNAL OF DIABETES (2014)
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
Jennifer B. Green et al.
AMERICAN HEART JOURNAL (2013)
TBS (Trabecular Bone Score) and Diabetes-Related Fracture Risk
William D. Leslie et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Safety of Antidiabetic Therapies on Bone
Beata Lecka-Czernik
CLINICAL REVIEWS IN BONE AND MINERAL METABOLISM (2013)
Intensive Glycemic Control Is Not Associated With Fractures or Falls in the ACCORD Randomized Trial
Ann V. Schwartz et al.
DIABETES CARE (2012)
Association between hypoglycaemic events and fall-related fractures in Medicare-covered patients with type 2 diabetes
S. S. Johnston et al.
DIABETES OBESITY & METABOLISM (2012)
Type 2 Diabetes and Bone
William D. Leslie et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
FRAX underestimates fracture risk in patients with diabetes
Lora M. Giangregorio et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures A meta-analysis of randomized clinical trials
Matteo Monami et al.
DIABETES CARE (2011)
FRAX (R) and its applications to clinical practice
John A. Kanis et al.
BONE (2009)
Rosiglitazone-associated fractures in type 2 diabetes - An analysis from a diabetes outcome progression trial (ADOPT)
Steven E. Kahn et al.
DIABETES CARE (2008)
Fracture risk in type 2 diabetes: Update of a population-based study
L. Joseph I. I. I. I. Melton et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients A case-control study
Matteo Monami et al.
DIABETES CARE (2008)
Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis
P. Vestergaard
OSTEOPOROSIS INTERNATIONAL (2007)
Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture
Mohsen Janghorbani et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study.
II de Liefde et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues
KM Thrailkill et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2005)
Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults - The health, aging, and body composition study
ES Strotmeyer et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk
P Vestergaard et al.
DIABETOLOGIA (2005)
Role of gastrointestinal hormones in postprandial reduction of bone resorption
DB Henriksen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Older women with diabetes have a higher risk of falls
AV Schwartz et al.
DIABETES CARE (2002)
Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women
KK Nicodemus et al.
DIABETES CARE (2001)
Validity of self-report of fractures: Results from a prospective study in men and women across Europe
AA Ismail et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
